Summary
35S-furosemide was administered orally (n=7) or i.v. (n=2) to healthy subjects. The average gastrointestinal uptake estimated by comparison of the urinary recovery of label and the areas under the plasma curves after the two routes of administration was 65%. The half life of radioactivity in the plasma after oral35S-furosemide was 90 ± 17 min (estimated on the slope between 2 and 6 h); the corresponding figure after35S-furosemide i.v. was 47–53 min (slope 0.5–4 h). There was probably a slower phase after 4–6 h. Fractionation of labelled material in urine from two subjects demonstrated that approximately two thirds of the label recovered at 24 h had the same chromatographic properties as furosemide. A major part of the metabolite(s) was probably furosemide glucuronide. There was no evidence that 4-chloro-5-sulfamoylanthranilic acid was formed in man. The total urinary recovery of label (5–7 d) after oral and intravenous administration was 55.1±3.2 (mean±SD) and 82–84%, respectively. After35S-furosemide i.v., 6–9% of the label was recovered in faeces, and it could not be accounted for solely by biliary excretion of furosemide.
Similar content being viewed by others
References
Beermann B., Hellström, K., Rosén, A.: Gastrointestinal absorption of certain anti-cholinergic drugs. Europ. J. clin. Pharmacol.5, 87–92 (1972)
Beermann, B.: On the fate of orally administered3H-lanatoside C in man. Europ. J. clin. Pharmacol.5, 11–18 (1972)
Bray, G.B.: A simple efficient liquid scintillator for counting aqueous solutions in liquid scintillation counter. Ann. Biochem. exp. Med.1, 279–285 (1960)
Calesnick, B., Christensen, J.A., Richter, M.: Absorption and excretion of furosemide-S35 in human subjects (31391). Proc. Soc. exp. Biol. (N.Y.)123, 17–22 (1966)
Cutler, R.E., Forrey, A.W., Christopher, T.B., Kompel, B.M.: Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin. Pharmacol. Ther.15, 588–596 (1974)
Hajdù P., Häussler, A.: Untersuchungen mit dem Salidiureticum 4-chlor-N (2-furylmethyl)-5-sulfamyl-antranilsäure. Arzneimittel-Forsch.14, 709–710 (1964)
Häussler, A., Wicha, H.: Untersuchungen mit dem Salidiureticum 4-Chlor-N-(2-furylmethyl)-5-sulfamyl-anthranilsäure. Arzneimittel-Forsch.15, 81–83 (1965)
Kelly, M.R., Cutler, R.E., Forrey, A.W., Kimpel, B.M.: Pharmacokinetics of orally administered furosemide. Clin. Pharmacol. Ther.15, 178–186 (1974)
Kindt, H., Schmid, E.: Über die Harnausscheidung von Furosemid bei Gesunden und Kranken mit Lebercirrhose. Pharmacol. Clin.2, 221–226 (1970)
Lindström, B., Molander, M.: Gaschromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector. J. Chromatogr.101, 219–221 (1974)
Rupp, W., Hajdú, P.: Pharmacokinetics and pharmacodynamics of a diuretic agent. In: Pharmacological and clinical significance of pharmacokinetics. (Ed. H.J. Dengler) pp. 105–111, Stuttgart-New York: F.K. Schattauer Verlag 1970
Rupp, W., Heidland, A., Hajdù, P. and Neuhans, G.: Pharmakokinetik von Furosemid bei normaler und eingeschränkter Nierenfunktion. In 4. Freiburger Tagung über Nephrologie 1970, Stuttgart: Thieme, pp. 207–213, 1970
Rupp, W., Zapf, R.M.: Beispiele zur Phase I: Diuretika. Arzneimittel-Forsch.23, 1665–1668 (1973)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beermann, B., Dalén, E., Lindström, B. et al. On the fate of furosemide in man. Eur J Clin Pharmacol 9, 57–61 (1975). https://doi.org/10.1007/BF00613429
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613429